About
Our Name
Mission
Values
Leadership
Board of Directors
Investors
Newsroom
Press Releases
In the News
Events
Contact
About
Our Name
Mission
Values
Leadership
Board of Directors
Investors
Newsroom
Press Releases
In the News
Events
Contact
PRESS RELEASE
Aristea Therapeutics Announces Dosing of First Patient in Phase 2a Trial of RIST4721 in Hidradenitis Suppurativa
August 30, 2022
2023 © Copyright. Aristea Therapeutics. All Rights Reserved.
